995P A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy

Abstract

Lysine methyltransferase 2D (KMT2D), which encodes a histone H3 lysine 4 methyltransferase, is one of the most frequently mutated genes in cancer patients. Previous studies showed that KMT2D-mutant tumor cell lines exhibited increasing immune infiltration and KMT2D mutation was correlated with higher tumor mutation burden (TMB) in multiple types of human cancers in TCGA datasets, suggesting that KMT2D-deficient tumors might be more sensitive to immune checkpoint inhibitors (ICIs), but the correlation of KMT2D mutation status with immune response in clinical remains unknown.